Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes sold 250,000 shares of Cardlytics stock in a transaction on Friday, September 13th. The stock was sold at an average price of $32.30, for a total value of $8,075,000.00.
Shares of Cardlytics stock opened at $34.10 on Thursday. The stock’s 50-day simple moving average is $33.69 and its 200-day simple moving average is $24.16. Cardlytics Inc has a 52 week low of $9.80 and a 52 week high of $39.62. The company has a market capitalization of $808.56 million, a price-to-earnings ratio of -15.93 and a beta of 1.53. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.79.
Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The business had revenue of $48.73 million for the quarter, compared to the consensus estimate of $43.77 million. During the same period in the previous year, the business earned ($0.21) earnings per share. The business’s revenue was up 37.0% on a year-over-year basis. On average, equities analysts expect that Cardlytics Inc will post -1.08 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can lifted its position in shares of Cardlytics by 16,371.4% in the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after acquiring an additional 1,146 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of Cardlytics in the second quarter worth about $60,000. Rockefeller Capital Management L.P. purchased a new stake in shares of Cardlytics in the second quarter worth about $85,000. Acadian Asset Management LLC purchased a new stake in shares of Cardlytics in the second quarter worth about $161,000. Finally, Royal Bank of Canada lifted its position in shares of Cardlytics by 166.5% in the second quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock worth $276,000 after buying an additional 6,649 shares in the last quarter. Institutional investors and hedge funds own 85.01% of the company’s stock.
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Featured Article: Marijuana Stocks
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.